In an exciting collaboration, modern mental health company, Clerkenwell Health, and Beckley Psytech, a clinical-stage biotechnology company, have launched a phase 2a study aimed at investigating a potential breakthrough treatment for alcohol use disorder...
No new treatments to combat the major public health issue of alcohol use disorder (AUD), have been brought to market for ten years - and with half of heavy drinkers refusing the abstinence route, new drug could be the answer.
We sat down with Cary Claiborne, CEO and president of Adial Pharma, to discuss the challenges of treating alcohol abuse and company's solution – a serotonin-3 receptor antagonist that could affect neurotransmitters like dopamine and modulate the...
Aegis Therapeutics has been granted a US patent for a novel formulation method and excipient that it claims reduces the risk of oxidative damage during MAb production and storage.
Arkema has unveiled a new green oxidation catalyst that it claims
"makes environmental protection a priority," as well as
launching a new product website.
Germany's Wacker Specialties has signed an R&D agreement with
Finland's Prokaria to bolster its activities in chiral alcohols,
used as chemical building blocks by the pharmaceutical industry.
BioCatalytics has expanded its product line of enzymes for chemical
synthesis with the addition of new ketoreductases (KRED) enzymes
for the stereoselective reduction of ketones.